Liver Steatosis and Steatohepatitis Alter Bile Acid Receptors in Brain and Induce Neuroinflammation: A Contribution of Circulating Bile Acids and Blood-Brain Barrier.
bile acid receptors
bile acids
blood brain barrier
brain inflammation
high-fat diet
intestinal inflammation
liver
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
17 Nov 2022
17 Nov 2022
Historique:
received:
20
09
2022
revised:
14
11
2022
accepted:
15
11
2022
entrez:
26
11
2022
pubmed:
27
11
2022
medline:
30
11
2022
Statut:
epublish
Résumé
A tight relationship between gut-liver diseases and brain functions has recently emerged. Bile acid (BA) receptors, bacterial-derived molecules and the blood-brain barrier (BBB) play key roles in this association. This study was aimed to evaluate how non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) impact the BA receptors Farnesoid X receptor (FXR) and Takeda G-protein coupled receptor 5 (TGR5) expression in the brain and to correlate these effects with circulating BAs composition, BBB integrity and neuroinflammation. A mouse model of NAFLD was set up by a high-fat and sugar diet, and NASH was induced with the supplementation of dextran-sulfate-sodium (DSS) in drinking water. FXR, TGR5 and ionized calcium-binding adaptor molecule 1 (Iba-1) expression in the brain was detected by immunohistochemistry, while Zonula occludens (ZO)-1, Occludin and Plasmalemmal Vesicle Associated Protein-1 (PV-1) were analyzed by immunofluorescence. Biochemical analyses investigated serum BA composition, lipopolysaccharide-binding protein (LBP) and S100β protein (S100β) levels. Results showed a down-regulation of FXR in NASH and an up-regulation of TGR5 and Iba-1 in the cortex and hippocampus in both treated groups as compared to the control group. The BA composition was altered in the serum of both treated groups, and LBP and S100β were significantly augmented in NASH. ZO-1 and Occludin were attenuated in the brain capillary endothelial cells of both treated groups versus the control group. We demonstrated that NAFLD and NASH provoke different grades of brain dysfunction, which are characterized by the altered expression of BA receptors, FXR and TGR5, and activation of microglia. These effects are somewhat promoted by a modification of circulating BAs composition and by an increase in LBP that concur to damage BBB, thus favoring neuroinflammation.
Identifiants
pubmed: 36430732
pii: ijms232214254
doi: 10.3390/ijms232214254
pmc: PMC9697805
pii:
doi:
Substances chimiques
Bile Acids and Salts
0
Occludin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Science. 2021 Nov 26;374(6571):1087-1092
pubmed: 34822299
Front Behav Neurosci. 2015 Mar 30;9:70
pubmed: 25870546
Am J Pathol. 2016 Feb;186(2):312-23
pubmed: 26683664
Front Aging Neurosci. 2016 Nov 22;8:263
pubmed: 27920719
Aliment Pharmacol Ther. 2021 Nov;54(10):1243-1262
pubmed: 34555862
Dig Liver Dis. 2022 Aug;54(8):1084-1093
pubmed: 34903499
Nat Metab. 2022 Apr;4(4):416-423
pubmed: 35338368
Glia. 2010 Nov 15;58(15):1794-805
pubmed: 20665558
Molecules. 2017 Aug 20;22(8):
pubmed: 28825644
Int J Mol Sci. 2020 Oct 20;21(20):
pubmed: 33092050
FASEB J. 2018 May;32(5):2866-2877
pubmed: 29401580
FASEB J. 2016 Nov;30(11):3658-3668
pubmed: 27468758
BMC Neurosci. 2008 Feb 26;9:29
pubmed: 18302779
Front Nutr. 2019 Jan 09;5:131
pubmed: 30687711
Front Neurosci. 2018 Feb 07;12:49
pubmed: 29467611
Molecules. 2022 Mar 18;27(6):
pubmed: 35335345
Trends Mol Med. 2022 Mar;28(3):223-236
pubmed: 35074252
Biomark Res. 2020 Nov 6;8(1):59
pubmed: 33292701
Pharmacol Ther. 2019 Nov;203:107396
pubmed: 31356908
Cell Metab. 2021 Jul 6;33(7):1483-1492.e10
pubmed: 33887197
Int J Mol Sci. 2020 Aug 20;21(17):
pubmed: 32825239
Front Immunol. 2021 Feb 22;11:609060
pubmed: 33692776
Int J Neuropsychopharmacol. 2020 Dec 10;23(10):673-686
pubmed: 32453814
Dig Liver Dis. 2014 Jun;46(6):527-34
pubmed: 24629820
J Cell Physiol. 2017 Aug;232(8):2231-2245
pubmed: 27987324
FEBS Lett. 2016 Sep;590(18):3233-42
pubmed: 27545319
Front Neurosci. 2017 Nov 07;11:617
pubmed: 29163019
Environ Toxicol. 2021 Jul;36(7):1412-1421
pubmed: 33749115
Inflamm Bowel Dis. 2014 Aug;20(8):1448-57
pubmed: 24983978
Cancer. 2003 Jun 1;97(11):2806-13
pubmed: 12767094
J Neurochem. 2015 Nov;135(3):565-76
pubmed: 26179031
Neuromolecular Med. 2021 Mar;23(1):99-117
pubmed: 33085065
Biochim Biophys Acta. 2016 Jul;1861(7):663-70
pubmed: 27086143
Front Neurosci. 2021 Nov 04;15:734158
pubmed: 34803583
Semin Immunopathol. 2022 Jul;44(4):547-564
pubmed: 35415765
J Neurochem. 2012 Mar;120(5):644-59
pubmed: 22145907
Cell Host Microbe. 2022 Mar 9;30(3):289-300
pubmed: 35271802
Neuroreport. 2021 Oct 6;32(14):1216-1222
pubmed: 34406989
Int J Mol Sci. 2019 Mar 11;20(5):
pubmed: 30862015
Anal Biochem. 2022 Apr 15;643:114436
pubmed: 34715070
Front Mol Neurosci. 2022 Jan 04;14:808603
pubmed: 35058750
Pharmacol Ther. 2021 Oct;226:107867
pubmed: 33895191
J Alzheimers Dis. 2021;84(2):461-477
pubmed: 34569953
Inflamm Res. 2015 Jan;64(1):9-20
pubmed: 25376338
Nat Med. 2018 Jul;24(7):908-922
pubmed: 29967350
Cell Mol Gastroenterol Hepatol. 2018 Apr 12;6(2):133-148
pubmed: 30023410
Biochem Biophys Res Commun. 2020 Feb 19;522(4):971-977
pubmed: 31810607
Neuropharmacology. 2022 Mar 1;205:108915
pubmed: 34919906